Tuesday, October 20, 2009

Winston Laboratories, Inc. Receives Notice of Non-Compliance in Canada for its New Drug Submission of CIVANEX to Treat Osteoarthritis

Oct 19, 2009 - Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced that it has received a Notice of Non-compliance from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

The details can be read here.

No comments: